Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
October 04 2021 - 7:30AM
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today
announced the appointment of Meera J. Desai, Ph.D., as a new
director and member of the company’s board of directors. Dr. Desai
replaces Roshawn Blunt, who retired from the Board effective
October 1, 2021.
Richard Williams, Chairman of the Board, commented: “We are
pleased to welcome Dr. Desai to the Board and look forward to
working with her to pursue long-term value creation. Her
substantial expertise in international pharmaceutical licensing,
combined with her background in drug development and
commercialization will help us refine corporate strategy to
maximize our product pipeline. I would also like to thank Roshawn
Blunt for her service on the board and for her contributions to
Adamis.”
Dr. Desai is the founder and managing partner of Silicon
Valley-based Karana Biotech, a boutique advisory firm focused on
guiding pharmaceutical and biotech clients through complex
international licensing, commercialization, and other strategic
transactions. Prior to founding Karana Biotech, she led corporate
development efforts for AcelRx Pharmaceuticals (NASDAQ: ACRX).
Previously, Dr. Desai was involved in pharmaceutical development
for Novartis Pharmaceuticals, Nektar Therapeutics, and ALZA
Corporation (a division of Johnson & Johnson). She holds a
Bachelor of Arts degree in chemistry from Drew University and a
Doctorate in Analytical Chemistry from Iowa State University. Dr.
Desai will serve on the Audit, Compensation, and the Nominating and
Governance committees of the Adamis Board.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
Company’s SYMJEPI (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. The Company’s resubmitted New
Drug Application for its naloxone injection product candidate,
ZIMHI, for the treatment of opioid overdose, is currently under FDA
review. Tempol is in development for the treatment of patients with
COVID-19 and a Phase 2/3 clinical trial is underway. For additional
information about Adamis Pharmaceuticals, please visit
www.adamispharmaceuticals.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those that express
plans, anticipation, intent, contingencies, goals, targets or
future development and/or otherwise are not statements of
historical fact. These statements relate to future events or future
results of operations, including, but not limited to the following
statements: and other statements concerning the Company’s future
operations and activities. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, which may cause Adamis' actual results to be materially
different from the results anticipated by such forward-looking
statements. We cannot assess the impact of each factor on our
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statements. You should not place
undue reliance on any forward-looking statements. Further, any
forward-looking statement speaks only as of the date on which it is
made, and except as may be required by applicable law, we undertake
no obligation to update or release publicly the results of any
revisions to these forward-looking statements or to reflect events
or circumstances arising after the date of this press release.
Certain of these risks and additional risks, uncertainties, and
other factors are described in greater detail in Adamis’ filings
from time to time with the SEC, including its annual report on
Form 10-K for the year ended December 31, 2020 and subsequent
filings with the SEC, which Adamis strongly urges you to read
and consider, all of which are available free of charge on
the SEC's website at http://www.sec.gov.
Contact:
Adamis Investor RelationsRobert UhlManaging DirectorWestwicke
ICR619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024